---
id: 117
title: Herpes Simplex Virus (HSV) Management
category: organisms
subcategory: viruses
tags: [HSV, HSV-1, HSV-2, encephalitis, acyclovir, valacyclovir, genital-herpes]
difficulty: medium
---

## Question

How is HSV managed by clinical syndrome? Use the **"Acyclovir for Severe/CNS, Valacyclovir for Mucocutaneous"** framework.

## Answer

### **HSV Types:**

- **HSV-1:** **Orolabial** herpes, **encephalitis**, keratitis
- **HSV-2:** **Genital** herpes (but HSV-1 also causes 30-50% of genital herpes)

### **Treatment by Clinical Syndrome:**

| Syndrome | Treatment | Duration | Notes |
|----------|-----------|----------|-------|
| **HSV Encephalitis** | **Acyclovir 10 mg/kg IV q8h** | **14-21 days** | **Start empirically** if suspected (don't wait for CSF PCR) |
| **Neonatal HSV** | **Acyclovir 20 mg/kg IV q8h** | **14-21 days** (SEM, CNS, disseminated) | High mortality if untreated |
| **Mucocutaneous (immunocompromised)** | **Acyclovir 5 mg/kg IV q8h** OR **valacyclovir 1g PO TID** | **7-14 days** | Until lesions heal |
| **Primary genital herpes** | **Valacyclovir 1g PO BID** OR **acyclovir 400mg PO TID** | **7-10 days** | **Shorten duration**, reduce viral shedding |
| **Recurrent genital herpes** | **Valacyclovir 500mg PO BID × 3 days** OR **acyclovir 800mg PO TID × 2 days** | **2-3 days** | **Episodic therapy** (patient-initiated) |
| **Suppressive therapy (genital)** | **Valacyclovir 500mg PO daily** OR **acyclovir 400mg PO BID** | **Long-term** | **Reduces recurrences**, **reduces transmission** |
| **Orolabial (cold sores)** | **Valacyclovir 2g PO BID × 1 day** OR **acyclovir 400mg PO 5×/day × 5 days** | **1-5 days** | Short course effective |

### **HSV Encephalitis:**

**Clinical Presentation:**
- **Fever, headache, confusion**, **focal neurologic deficits**
- **Temporal lobe** involvement (seizures, personality changes)
- **MRI:** Temporal lobe abnormalities (hyperintensity on T2/FLAIR)

**Diagnosis:**
- **CSF PCR for HSV** (sensitivity 95-100%)
- **CSF:** Lymphocytic pleocytosis, ↑protein, normal glucose, **RBCs** (hemorrhagic)

**Treatment:**
- **Acyclovir 10 mg/kg IV q8h × 14-21 days**
- **Start empirically** if suspected (don't wait for PCR results)
- High mortality if untreated (70%), reduced to 20-30% with treatment

## Key Points

### **Acyclovir vs Valacyclovir:**
- **Acyclovir:** IV for severe, PO requires 5× daily dosing
- **Valacyclovir:** **Prodrug of acyclovir**, **better oral bioavailability** (3× higher), BID-TID dosing (preferred for oral therapy)
- **Famciclovir:** Alternative oral agent (similar efficacy)

### **Resistance:**
- **Rare** in immunocompetent (<1%)
- **More common** in immunocompromised (HIV, transplant) with prolonged/repeated courses
- **Mechanism:** Thymidine kinase deficiency
- **Treatment:** **Foscarnet 40 mg/kg IV q8h** OR **cidofovir**

### **Suppressive Therapy (Genital Herpes):**
- **Reduces recurrences** by 70-80%
- **Reduces transmission** by ~50%
- **Indications:** ≥6 recurrences/year, patient preference, **serodiscordant couples**
- **Valacyclovir 500mg daily** (or 1g daily if ≥10 recurrences/year)

### **Neonatal HSV:**
- **High mortality** (disseminated 30%, CNS 4%)
- **Risk factors:** Primary maternal infection near delivery, prolonged rupture of membranes, **fetal scalp monitoring**
- **Acyclovir 20 mg/kg IV q8h** × 14 days (SEM) or 21 days (CNS/disseminated)
- **Cesarean delivery** if active genital lesions at delivery

### **Clinical Pearls:**
- **HSV encephalitis:** Acyclovir 10 mg/kg IV q8h × 14-21 days (**start empirically**)
- **Valacyclovir** preferred for oral therapy (better bioavailability, less frequent dosing)
- **Suppressive therapy** reduces recurrences + transmission (valacyclovir 500mg-1g daily)
- **Primary genital:** 7-10 days, **recurrent:** 2-3 days (patient-initiated)
- **Resistance:** Foscarnet if acyclovir-resistant
- **CSF PCR** gold standard for encephalitis diagnosis

## Sources

- [IDSA: HSV Encephalitis Guidelines 2024]
- [CDC: Genital Herpes Treatment Guidelines 2024]

## Media

N/A
